Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Novartis site directory
Our Products
US Products By Brand
Patient Assistance
Product Portfolio
Our Process
Therapeutic Areas
Product Related Issues
About Us
Novartis US at a Glance
Who We Are
Diversity and Inclusion
Our Leadership
Supplier Diversity
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to HCPs & HCOs
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2020
May
Media Release
/
May 06, 2020
Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14
Read More
April
Media Release
/
Apr 03, 2020
Novartis and the Novartis US Foundation establish USD 5 million US COVID-19 Community Response Fund
Read More
March
Media Release
/
Mar 28, 2020
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Read More
Media Release
/
Mar 28, 2020
Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Read More
Media Release
/
Mar 18, 2020
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
Read More
Media Release
/
Mar 18, 2020
Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements
Read More
February
Media Release
/
Feb 11, 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Read More
January
Media Release
/
Jan 16, 2020
Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
Read More
2019
December
Media Release
/
Dec 11, 2019
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
Read More
Media Release
/
Dec 09, 2019
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
…
Page
2
of 5
Page
3
of 5
Current page
4
of 5
Page
5
of 5
Page
6
of 5
…
Next page
next ›
Last page
last »
Share
Email
Jump to Comments
Print
Save
Related Links
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
You are here
Home
›
News